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INTRODUCTION
Although it is well-known that the administration of antenatal corticosteroids to
mothers at risk of preterm birth improves outcomes in premature infants, premature births
and associated morbidity and mortality are still prevalent. Typical mortality associated
with premature births account for approximately one-third of all infant deaths in the United
States. Infants born before 25 weeks gestation have the highest mortality rate, and if they
survive, are at the greatest risk for severe morbidity, which translate into higher risk of
hospital readmission and significant medical costs. Premature neonates are at a higher
risk for acute complications, including necrotizing enterocolitis, growth difficulties, sepsis,
intracranial bleeding, retinal detachment, bronchopulmonary dysplasia, chronic lung
disease, and death. In early childhood, morbidities include motor delay, cerebral palsy,
lower IQs, behavior problems, respiratory illness, difficulty with school work, and lower
health-related quality of life.
For those reasons, corticosteroid administration prior to anticipated preterm birth
is one of the most important and effective antenatal therapies available to improve
newborn outcomes. The American College of Obstetricians and Gynecologists (ACOG)
currently recommends the administration of a single course of antenatal corticosteroids
for pregnant women between 24 0/7 weeks and 33 6/7 weeks of gestation at risk of
preterm delivery within 7 days1. A Cochrane meta-analysis concluded with a
recommendation that a single course of antenatal corticosteroids should be given for all
preterm deliveries2. However, one study showed multiple courses of antenatal
corticosteroids were associated with a lower incidence of respiratory distress syndrome
(P=.005; odds ratio, 0.44; 95% confidence interval, 0.25-0.79), patent ductus arteriosus
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(20% vs 13%; P=.016), and mothers treated with multiple courses had a lower incidence
of prolonged rupture of membranes (24% vs 33%; P=0.6)3. This paper reviews whether
a single course of antenatal corticosteroid therapy compared to multiple courses of
antenatal corticosteroid therapy in preterm infants is necessary to prevent mortality and
disability within 10 years. Multiple versus single courses of betamethasone and
dexamethasone will be examined as it is prudent to prevent premature births and assess
the long-term risks and benefits of antenatal corticosteroids.
DISCUSSION
To answer this question, the current literature was searched using keywords and
MeSH terms such as antenatal corticosteroids, single v. weekly course, long-term
outcomes, and premature births. Online biomedical literature databases such as PubMed
Central, Google Scholar, JSTOR, MEDLINE, and ACOG were searched. The relevant
articles were filtered by limiting the selection to double-blinded, placebo-controlled, or
randomized studies and then organized by publication date. In each trial, the long-term
effects of a single dose or placebo of antenatal corticosteroids were compared with
multiple doses.
In a meta-analysis of 11 full-text randomized controlled trials, benefits and risks of
multiple courses of antenatal corticosteroids were investigated in 4,390 women and 5,227
neonates4. Groups given multi-courses of antenatal corticosteroids were associated with
a significant decrease in respiratory distress syndrome, patent ductus arteriosus,
ventilator support, surfactant use, and maternal side-effects compared to groups given a
single-course of antenatal corticosteroids. This meta-analysis strengthened the
association between multiple-courses of antenatal corticosteroids and reduced

3

complications in neonates. However, no details on the number of reviewers for the study
selection process, data collection, or quality assessment were provided.
In a randomized, double-blind, placebo-controlled, intention-to-treat trial, effects of
single vs. weekly courses of antenatal corticosteroids on neonatal morbidity and mortality
were investigated in 502 pregnant women across 13 U.S. academic centers, but 32
women withdrew and 4 women were withdrawn by their Obstetrician5. No statistically
significant reduction in neonatal morbidity and mortality (i.e., respiratory distress
syndrome, bronchopulmonary dysplasia, severe IVH, sepsis, perinatal death, necrotizing
enterocolitis) were noted between single vs. weekly courses of ACS. This trial was
randomized, double-blind, and placebo-controlled, so the findings should not be
preferentially biased. However, this investigation was limited by a lack of standardization
of cranial ultrasonography and for neonatal biometry determinations. The table below
summarizes Guinn et al.’s findings.
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(Excerpted from: Guinn, D. A., Atkinson, M. W., Sullivan, L., Lee, M., Macgregor, S., Parilla, B. V.,
Muraskas, J. (2002). Single vs Weekly Courses of Antenatal Corticosteroids for Women at Risk of Preterm
Delivery: A Randomized Controlled Trial. Obstetrical & Gynecological Survey, 57(3), 146-147.
doi:10.1097/00006254-200203000-00008)

The Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study (MACS)
investigated morbidity and mortality in infants exposed to placebo versus multiple
antenatal corticosteroids at birth6. 1,858 women at 25-32 weeks gestation at high risk of
preterm delivery were randomly assigned to multiple courses of antenatal corticosteroids
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(n=937) or placebo (n=921), every 14 days until week 33 or delivery, whichever came
first. Analysis of perinatal or neonatal mortality, severe respiratory distress syndrome,
intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia,
and necrotizing enterocolitis was completed with intention to treat. No statistically
significant reductions in neonatal morbidity and mortality were seen in infants exposed to
multiple courses of antenatal corticosteroids versus placebo. However, infants who
received multiple courses of antenatal corticosteroids were associated with a decreased
weight (2216 g vs 2330 g, p=0.0026), decreased length (44.5 cm vs 45.5 cm, p<0.001),
and smaller head circumference (31.1 cm vs 31.7 cm, p<0.001) at birth. This study has
methodological strength as it is a randomized controlled study.
In a cohort follow-up study of these MACS participants, the effects of single vs.
multiple courses of antenatal corticosteroids on morbidity and mortality were investigated
at 2 years and 5 years of age in children whose mothers participated in MACS between
25 and 32 weeks gestation and remained pregnant 14 to 21 days following an initial
course of antenatal corticosteroids7. Of 2,305 infants eligible for follow-up evaluation,
2,104 infants were evaluated at 18 to 24 months of age. Although more than 90% of the
cohort successfully followed up after 2 years, no statistically significant differences were
found for the risk of death, neurologic impairment, height, weight, and head circumference
between infants in the multiple antenatal corticosteroid group (n=1,069) and the placebo
group (n=1,035).
To investigate 5-year outcomes of these MACS participants, 1,728 children were
selected by central randomization with stratification according to center and gestational
age at enrollment8. Although more than 80% of the cohort successfully followed up after
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5 years, no statistically significant differences were found for the risk of death,
neurodevelopmental disability, weight, head circumference, and visual-motor abilities and
integration. Due to the lack of evidence supporting short-term and long-term benefits,
multiple courses of antenatal corticosteroids were not recommended in women at risk for
preterm delivery.
In a retrospective review, medical records of 256 preterm newborns with and
without maternal use of antenatal corticosteroids were evaluated9. Of the 256 total infants,
174 neonates went without maternal use of antenatal corticosteroids, 37 infants received
a single dose and 45 infants received multi-courses of antenatal corticosteroids. Over the
10 years examined, the incidence of intubation and surfactant use were significantly less
in single and multi-dose corticosteroid groups compared to groups without maternal use
of antenatal corticosteroids. No statistical significance in the rate of survival, IVH, NEC,
retinopathy of prematurity, long-term neurologic outcomes, or neonatal sepsis were found
among the 3 groups. The findings in this 10-year retrospective review revealed that
infants of mothers who received both single and multiple doses of antenatal
corticosteroids had fewer respiratory interventions than infants without maternal use of
antenatal corticosteroids.
In a randomized, controlled trial the neurodevelopment and health outcomes of
2-mL Celestone Chronodose versus placebo were investigated in 1,146 infants10. At ages
6-8 years, children were evaluated by a pediatrician. Of the infants who were given a
single dose of antenatal corticosteroids, 41% developed respiratory distress syndrome
and 20% developed severe lung disease. Treatment with repeated doses of antenatal
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corticosteroids, however, significantly decreased these adverse respiratory outcomes. Of
note is that lung function of most children was not reported in this study.
In an observational study, the 3-year outcomes of repeated antenatal
corticosteroids on birth size, growth, and development were followed in 477 singleton
infants enrolled in a regional cohort study11. Of the infants who were given single versus
multiple doses of antenatal corticosteroids, birth weight ratio and head circumference
significantly decreased with increasing number of corticosteroids courses. Reduction of
head circumference by 4% represents approximately 11% reduction in cranial volume.
This is a critical finding as poor developmental, intellectual, and behavioral outcomes are
associated with small head circumference in preterm infants. This significant decrease in
birth weight ratio with multiple courses of antenatal corticosteroids was seen regardless
of pregnancy complications (i.e., preeclampsia, preterm labor rupture of membranes,
antepartum hemorrhage, idiopathic preterm labor). Notably, the group that had received
3 or more courses of corticosteroids showed a higher frequency of severe chronic lung
disease. Of the 477 infants, 385 survived to 3 years. Univariate and multivariate analyses
of weight, height, and head circumference at age 3 did not show any differences between
antenatal corticosteroids groups. However, the relationship between antenatal
corticosteroid use and behavioral outcomes was not analyzed.
CONCLUSION
The evidence in the available literature does not answer whether single or multiple
ACS is preferable. These conflicting statistically significant results call for further research
on the efficacy of single versus multiple courses of antenatal corticosteroids. Based on
these findings, further research on any associations between antenatal corticosteroid
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therapy and the development of chronic illnesses is warranted. The results of future
research may have a great impact on clinical practice as it is prudent to prevent premature
births and reduce the long-term risks and benefits of antenatal corticosteroids.
One limitation noted across several studies was the small sample size of women at risk
for preterm delivery. Prospective randomized controlled trials with larger sample sizes are
recommended to circumvent limitations of future studies. Another limitation is that most
studies were either retrospective or observational and may have relied heavily on
associations; therefore, caution should be used when generalizing and applying the
results in these studies.
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